DataMEDS AI, Inc. cash flow to debt ratio of 0.00% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

DataMEDS AI, Inc. has insufficient data to evaluate this check.

DataMEDS AI, Inc. has insufficient data to evaluate this check.

DataMEDS AI, Inc. has insufficient data to evaluate this check.

DataMEDS AI, Inc. has negative EBITDA, making leverage ratio unreliable

Interest expense is not separately reported in DataMEDS AI, Inc.'s latest filing, so interest coverage cannot be calculated.

DataMEDS AI, Inc.'s profit margin has decreased (1.34K%) in the last year from -37.82% to -545.72%, signaling decreasing performance

DataMEDS AI, Inc. has insufficient data to evaluate this check.

DataMEDS AI, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

DataMEDS AI, Inc.'s return on equity of 1.55K%, is higher than 15.00%, indicating good performance

DataMEDS AI, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

DataMEDS AI, Inc. has insufficient public price history to evaluate earnings stability.

DataMEDS AI, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

DataMEDS AI, Inc. has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value

DataMEDS AI, Inc.'s yearly earnings has decreased 1.38K% since last year from $-6.86M to $-101.27M, signaling decreasing performance

DataMEDS AI, Inc.'s yearly revenue has increased 28.73% since last year from $18.13M to $23.34M, signaling increasing performance

ROIC -403.31% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

DataMEDS AI, Inc.'s 3-year revenue CAGR of -10.70% is negative, indicating declining revenue over the past 3 years

DataMEDS AI, Inc. has insufficient public price history to evaluate revenue consistency.

DataMEDS AI, Inc. has insufficient public price history to evaluate ROE consistency.

DataMEDS AI, Inc. has insufficient data to evaluate this check.

DataMEDS AI, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

DataMEDS AI, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

DataMEDS AI, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

DataMEDS AI, Inc. has insufficient data to evaluate this check.

DataMEDS AI, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

DataMEDS AI, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

DataMEDS AI, Inc. has a price-to-sales ratio of 0.16x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue